Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded to Strong-Buy by StockNews.com

Jazz Pharmaceuticals (NASDAQ:JAZZ) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Thursday.

Other equities analysts also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $195.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. UBS Group cut their price target on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a report on Friday, March 1st. Needham & Company LLC cut their price target on shares of Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating on the stock in a report on Thursday, June 20th. Finally, The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, June 5th. They issued a “buy” rating and a $169.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $190.00.

Jazz Pharmaceuticals Stock Down 0.1 %

Shares of JAZZ traded down $0.06 during mid-day trading on Thursday, hitting $107.10. 542,602 shares of the company traded hands, compared to its average volume of 693,542. Jazz Pharmaceuticals has a 1-year low of $103.01 and a 1-year high of $146.70. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The company has a market capitalization of $6.75 billion, a PE ratio of 22.08, a price-to-earnings-growth ratio of 1.66 and a beta of 0.62. The business has a 50 day moving average of $109.00 and a 200 day moving average of $116.87.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The company had revenue of $901.98 million for the quarter, compared to analyst estimates of $938.99 million. Equities research analysts anticipate that Jazz Pharmaceuticals will post 15.35 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now owns 36,629 shares in the company, valued at approximately $4,016,369.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rise Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 203 shares in the last quarter. Cape Investment Advisory Inc. lifted its holdings in Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after purchasing an additional 292 shares in the last quarter. Assetmark Inc. lifted its holdings in Jazz Pharmaceuticals by 37.1% in the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 119 shares in the last quarter. Headinvest LLC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $56,000. Finally, Newbridge Financial Services Group Inc. lifted its holdings in Jazz Pharmaceuticals by 254.5% in the 4th quarter. Newbridge Financial Services Group Inc. now owns 468 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 336 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.